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S U M M A R Y
Chronic osteomyelitis is a relatively common infection and is often a lifelong disease. Traditionally,
osteomyelitis has been treated with 4–6 weeks of parenteral antibiotics after deﬁnitive debridement
surgery. Antibiotic-impregnated cement beads have also been used as adjuvant therapy for chronic
osteomyelitis. However, this time frame of antibiotic treatment has no documented superiority over
other time intervals, and there is no evidence that prolonged parenteral antibiotics will penetrate the
necrotic bone. There is no solid evidence in the medical literature to support the continuous use of long
duration antibiotic treatment for chronic osteomyelitis. A small number of comparative trials on the
treatment of chronic osteomyelitis have been published. Also, the type of surgical procedures practiced
in the past in treating chronic osteomyelitis and the lack of effective muscle ﬂap application might have
contributed to the prolonged antibiotic treatment. And although the surgical approach to the treatment
of chronic osteomyelitis has advanced markedly, still the same duration of antibiotic treatment is
adopted. In this reviewwe question the continuous and traditional use of long-term antibiotic treatment
for chronic osteomyelitis in spite of the advances in surgical treatment using ﬂaps. The medical
literature, including studies in animals and humans, was searched for evidence to support the use of
short courses of antibiotics.We hope this reviewwill provoke the initiation of animal studies and clinical
trials assessing the use of short courses of antibiotics for chronic osteomyelitis.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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From the time of the famous painting, ‘‘The Gross Clinic’’ by T.
Eakins, until today, considerable advancements have been made
for the surgical treatment of chronic osteomyelitis. However, the
lack of aseptic concepts at that time can be equated with the
current lack of deﬁnite guidelines regarding the duration of
antibiotic therapy. Most physicians have prescribed prolonged
courses of antibiotics in treating chronic osteomyelitis. This has
been traditionally adopted, though it is not based on strong
evidence. And although the surgical techniques in treating chronic
osteomyelitis have advanced considerably, still the duration of
antibiotic treatment has not decreased.
In this reviewwe question the continuous and traditional use of
long-term antibiotic treatment for chronic osteomyelitis in spite of
the advances in surgical treatment using ﬂaps. The medical
literature was searched for evidence in animal and human studies
to support the use of short courses of antibiotics. We hope this
review will provoke the initiation of animal studies and clinical* Corresponding author. Tel.: +961 3310877; fax: +961 1366384.
E-mail address: rh00@aub.edu.lb (R. Haidar).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.01.005trials assessing the use of short courses of antibiotics for chronic
osteomyelitis.
Chronic osteomyelitis is an osseous infection that has
progressed to bone necrosis and sequestrum formation.1–3
Pathologic features of chronic osteomyelitis are the presence of
necrotic bone and the exudation of polymorphonuclear leukocytes
joined by large numbers of lymphocytes, histiocytes, and
occasionally plasma cells.3 Symptoms are usually vague and the
historymight include chronic pain, chills, and low-grade fever. The
physical examination might reveal local swelling and drainage.
Diagnosis of chronic osteomyelitis is based on medical history,
laboratory ﬁndings, and different imaging techniques.4 Laboratory
tests may reveal a normal leukocyte count but elevated erythro-
cyte sedimentation rate (ESR) and C-reactive protein (CRP) levels.
The imaging modalities used for detecting the infection include X-
ray, computed tomography (CT) scan, and magnetic resonance
imaging (MRI). Technetium-99m labeled leukocyte imaging helps
eliminate differential diseases, and bone cultures guide the
antimicrobial drug choice.1
2. Treatment of osteomyelitis
Treatment of osteomyelitis in the long bones requires a multi-
domain intervention incorporating speciﬁc surgical approachesses. Published by Elsevier Ltd. All rights reserved.
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procedure can be summarized as two basic steps, namely
debridement and obliteration of the subsequent dead space by
soft tissue. Other techniques such as removal of hardware or
fracture stabilization may be used when necessary for a better
functional and therapeutic outcome.1
3. Debridement
Debridement has been the forefront management protocol in
osteomyelitis.5 It includes excision of all sequestra along with any
infected bone or soft tissue,2 followed by obliteration of residual
dead space. However, the involucrummay be preserved because it
is viable bone; periosteum stripping and cortex resection are
carefully approached to prevent unnecessary loss of vasculariza-
tion and stability.6 The delineation of involucrum, inﬂammation,
and its penetration can be planned pre-operatively based on
standard radiographs, CT scan, MRI or bone scan.5 However, the
ﬁnal margin of debridement is determined by the surgeon intra-
operatively5 by the paprika sign,3 demonstrated by interspersed
pin-pointed bleeding noted on the well-vascularized viable bone.6
The degree of tissue to be removed can be decided beforehand to
follow wide excision in a compromised host but marginal excision
in otherwise healthy patients.7 Insufﬁcient debridement is
correlated with a high recurrence rate in chronic osteomyelitis,2
where the failure/recurrence rate may reach 30%.5 To decrease the
recurrence rate, the management of chronic osteomyelitis of the
long bones sometimes requires segmental resection, application of
external ﬁxator, and immediate or delayed metaphyseal corticot-
omy.
Thus, the quality and extent of debridement is a crucial step
towards successful management.8 Adequately performed aggres-
sive debridement reduces the microbial load,9 eradicates dead
sections, and rescues healthy viable segments,3 but it also leaves
behind a signiﬁcant dead space of bone and soft tissue.6
4. Soft tissue coverage
The avascular dead space resulting fromdebridement promotes
persistence of the infection.3 Therefore, it is necessary to properly
manage this space8 in order to prevent recurrence2 and sustain
bone integrity.3 Obliteration of the dead space is achieved with
durable vascularized soft tissues3 that may be local, if adequate
and not severely scarred, or distant, either pedicled or free.8 These
ﬂaps range from the simplest skin ﬂaps9 for small space coverage3
to fasciocutaneous and muscular ﬂaps9 for bulk coverage.3 Soft-
tissue ﬂaps improve local blood ﬂow and antibiotic delivery.8
As early as 1946, Stark demonstrated that for the treatment of
chronic osteomyelitis, rotating local muscles into post-debride-
ment cavities resulted in an 84% success rate compared to only
43% when local ﬂaps were not rotated.10 Subsequently, the
superiority of axial muscle ﬂaps over random-pattern skin ﬂaps
was demonstrated.10,11 Today, muscle ﬂaps are considered to be
the best option for reconstructing chronic osteomyelitic
wounds,12,13 with the latissimus dorsi and rectus abdominis
being the most common muscles used in free-transfer proce-
dures.14 The advantages of a muscle ﬂap can be attributed to its
good blood ﬂow, antibiotic release, and oxygen tension.12
However, muscle ﬂaps have certain drawbacks: the functional
donor-site morbidity14 and their bulk, which might not be highly
aesthetic.12 Fasciocutaneous ﬂaps may avoid these problems;12
however, their utilization for the treatment of osteomyelitis has
been limited, with conﬂicting outcomes. Experimental results
revealed the superiority of muscle ﬂaps in reducing bacterial
growth even though fasciocutaneous ﬂaps showed a more robust
early increase in oxygen tension.14Nonetheless, recent data show that optimal vascularization
of any ﬂap is the most important characteristic to provide
efﬁcient coverage of dead space and to ensure success of
treatment following adequate debridement.13,15 It is worth
noting that muscle ﬂaps may conform better than fasciocuta-
neous ﬂaps to cavities and thus may be superior in obliterating
dead spaces.
5. Antibiotic treatment
The surgical procedure may include or be preceded by biopsy
harvesting for planning the antibiotic treatment. Once the
microbial agent is identiﬁed by culture, the broad-spectrum
antibiotic initiated post-operatively is changed according to the
culture and sensitivity results.15 It should be noted that in chronic
osteomyelitis, bone and non-bone specimens might vary drasti-
cally in their microbiology; hence, microbiological studies of the
bone should be considered for any therapeutic approach.15,16
Further management will be dictated by the patient’s status,
clinical response, and risk of adverse effects.17 Concerning the
duration of treatment for chronic long-bone osteomyelitis in
adults, intravenous administration of antibiotics for 4–6 weeks is a
widely used protocol.17,18 However, the duration of therapy
remains empiric.1 This is because there are no clinical studies or
documented records indicating the superiority of the 4–6-week
course of antibiotics over other durations.19,20
6. Antibiotic-impregnated cement beads
In the 1970s, antibiotic-impregnated bone cement was intro-
duced as local antibacterial therapy to treat infected arthroplas-
ties.21 Since then, antibiotic-impregnated beads have been
developed to treat local infections of bone and soft tissue. The
advantage of antibiotic-containing beads is that the beads ﬁll dead
space produced by debridement and they provide local antibiotic
concentrations that are much greater than the minimum
inhibitory concentration formost pathogens isolated in orthopedic
infections.22,23 The local release of antibiotics accomplished with
antibiotic-impregnated beads avoids the potential systemic
adverse effects.22,24,25 Compared with systemic antibiotic therapy,
the incidence of nephrotoxic, ototoxic, and hypersensitivity
reactions with antibiotic-impregnated beads is signiﬁcantly
diminished.22,26,27
The effectiveness of local antibiotic administration using
antibiotic-impregnated beads in the treatment of osteomyelitis
has been widely demonstrated. Korkusuz et al. reported on the
effectiveness of antibiotic-impregnated beads in the treatment of
osteomyelitis in a rat model.28 In another chronic osteomyelitis
model, the efﬁcacy of gentamicin bead treatment was comparable
to treatment with systemic antibiotics.29 Other investigators have
obtained good results in other animal models.30,31
Most of the data reported in the literature support the safe
usage of antibiotic-impregnated beads.23,29,32 These antibiotic
beads have been used in the treatment of chronic osteomyelitis,
mostly as a supplement to systemic antibiotic treatment.33,34
Therewas no recurrence in 12 treated patients. One study reported
26 patients with chronic osteomyelitis treated with radical
debridement, irrigation, vancomycin-impregnated beads and
systemic antibiotics.32 The results were satisfactory in all patients,
who were ambulatory and had returned to their pretreatment
activity level or better at last follow-up.32 A study from Germany
reported a high cure rate (91.4%) in a group of 128 patients treated
for different manifestations of chronic osteomyelitis.25
In vivo models comparing the efﬁcacy of antibiotic-impregnat-
ed cement beads to systemic antibiotics are lacking. For the time
being, antibiotic-impregnated beads are effective supplements to
Table 1
Animal studies on the treatment of osteomyelitis
Reference Disease case Antibiotic treatment Antibiotic duration
Salgado et al. 2006 [14] Osteomyelitis of lower extremity of goat Cefazolin 5 days
Norden et al. 1980 [35] Staphylococcal chronic osteomyelitis in rabbit Rifampin and trimethoprim 7, 14, 28 days
Norden 1983 [36] Staphylococcal osteomyelitis Rifampin, sisomicin, and cephalothin 14 days
Norden and Shaffer 1982 [37] Chronic osteomyelitis in rabbit, Pseudomonas
aeruginosa
Azlocillin and tobramycin 14, 28 days
Mader and Wilson 1983 [38] Staphylococcal osteomyelitis in rabbit Cefamandole or cephalothin 28 days
Rissing et al. 1985 [39] Staphylococcal chronic osteomyelitis in rat Oxacillin or ceftriaxone 14, 28 days
Nelson et al. 1990 [40] Chronic Pseudomonas aeruginosa osteomyelitis in rat Subcutaneous ceftazidime alone or in
combination with tobramycin
14 days
Dart and Hodgson 1996 [41] Chronic osteomyelitis in horse Penicillin and gentamicin 10 days
Monzon et al. 2001 [42] Staphylococcal chronic osteomyelitis in rat Cefuroxime, vancomycin, tobramycin
or ciproﬂoxacin
21 days
Shirtliff et al. 2001 [43] Staphylococcal chronic osteomyelitis in rabbit Levoﬂoxacin and nafcillin 28 days
Kadry et al. 2004 [44] Chronic staphylococcal osteomyelitis in rabbits Ciproﬂoxacin and vancomycin
(liposomal form of the combination)
14 days
Yin et al. 2005 [45] Methicillin-resistant Staphylococcus aureus
osteomyelitis
Subcutaneous tigecycline or vancomycin
with or without oral rifampin
28 days
R. Haidar et al. / International Journal of Infectious Diseases 14 (2010) e752–e758e754debridement and systemic antibiotics in the treatment of soft-
tissue infections and chronic osteomyelitis.
7. Materials and methods
The medical databases of PubMed, Medline, and Embase were
searched for literature on treatment modalities of chronic
osteomyelitis (MeSH term) in the lower extremities; hence acute,
maxillofacial, and vertebral osteomyelitis entries were excluded,
as were those of ‘diabetic foot’. Later, the search was combined
with ‘antibacterial agents’ (MeSH term)/antibiotic. The medical
literature was reviewed for articles published between 1955 and
2008. All entries in the English language were scanned for related
information and the most appropriate references included in this
manuscript. Those related to animal studies are summarized in
Table 1 and those related to human studies are summarized in
Table 2. We wished to update the reader and the orthopedic
surgeon on what has been documented in the literature
concerning the treatment of chronic osteomyelitis, evaluating
whether there is any evidence supporting certain durations of
antibiotic treatment.
8. Results and discussion
8.1. Animal studies
Starting in the 1970s, animal studies were undertaken in order
to determine the appropriate duration of antibiotic treatment for
osteomyelitis (Table 1).14,35–45 Rabbit models of chronic osteomy-
elitis indicated that clindamycin administered for 28 days was
effective in treating the bone infection, while 4-week courses of
penicillin and cephalosporin were not sufﬁcient for adequate
therapy.35
On the other hand, these single-antibiotic studies were
contradicted by the combination-drug studies showing therapy
success with courses shorter than 4 weeks.35 One study in rabbits
revealed that staphylococcal osteomyelitis treated with the
combination of rifampin, sisomicin, and cephalothin had a lower
percentage of positive bone cultures thanwhen rifampinwas given
alone or in combination with other antibiotics.36 Furthermore,
lower rates of positive culture were obtained with 7-, 14-, and 28-
day treatment modalities. It is worth mentioning that the therapy
was started 14 days after the induction of infection, the cultures
were done after 70 days of treatment, and no surgical procedure
was attempted in that study.36 Another study conducted a few
years later by the same investigator indicated that rabbitsreceiving the combination of rifampin, sisomicin, and cephalothin
for only 14 days recovered from staphylococcal osteomyelitis.37
Studies on the angiogenesis and blood ﬂow in osteomyelitic
bone are scarce. In a recent study by Herzog et al., blood ﬂow in the
fractured tibia of rabbits was studied after introducing the muscle
ﬂap. A rise in perfusion rate was noticed in the cortical lid within
the ﬁrst week after local muscle ﬂap transfer.46 Another study on
goats illustrated that the osteomyelitic bones reconstructed with a
very well-vascularized ﬂap, being of muscle or non-muscle origin,
were able to recover with only 5 days post-operative antibiotic
administration.14 Although healing in chronic osteomyelitis will
depend on the rapidity of revascularization, which is linked to
angiogenesis, researchers have still not conducted studies to assess
this notion. Studies on angiogenesis and revascularization are
needed to understand this concept in chronic osteomyelitis and to
explore what factors might speed up this process, eventually
leading to rapid healing and shorter courses of antibiotic
treatment.
8.2. Human studies
After an extensive search of the literature on osteomyelitis, all
studies using a short-term antibiotic course (3–14 days),
irrespective of the outcome, are summarized in Table 2.47–67 We
have not included studies using the traditional 6-week antibiotic
regimens because these studies have been extensively reviewed by
many investigators in the medical literature.68,69
Most of the reviewed studies showed good results in treating
chronic osteomyelitis. The therapy duration might be shortened
depending on the administration route of the drug. Treatment
failure can be attributed to many factors. For example, a study on
patients suffering from infectious diseases included as part of its
population a small set of six chronic osteomyelitis cases.68 These
patients were treated for 11–24 days (average of 15 treatment
days) post-operatively (hardware removal, stabilization of non-
union and bone graft, when indicated) with cefoxitin, with a good
response in four of the cases. Failure was due to the retained metal
wire and the non-union of the femur, which facilitated the
persistence of infection.68
‘‘By 1968, Bick’s book reviewing 25 years of experience with
antibiotic treatment led him to conclude that it was invaluable for
eliminating osteomyelitis-related septicemia and abscesses, but
that chronic bone infection could only be cured with surgery’’.36
Thus, it is fully established that without proper surgical interven-
tion and debridement, the treatment failure rate in chronic
osteomyelitis is high, irrespective of the duration of the antibiotic
Table 2
Chronic osteomyelitis cases of the lower extremities treated with short term antibiotics reported in the literature
Reference Cases Surgical procedure Antibiotics used Antibiotic duration Outcome
Geddes et al. 1964 [47] 5 patients, osteomyelitis
of tibia or femur
Lincomycin 4, 7, 18 weeks for 3 patients and
1 week for 2 patients
3 patients recovered; failure in 2
Grondin et al. 1965 [48] 6 patients with chronic
osteomyelitis of lower
extremities (2 tibia, 3 femur)
Drainage and graft for 2 cases Lincomycin Average of 17.4 days (5–30 days) 5 patients responded
Nettles et al. 1969 [49] 2 patients with chronic
osteomyelitis (femur and
intermedullary nail)
Debridement and saucerization
for 1 patient
Cephalothin or tetracycline 2–3 weeks Good in all
Edmondson 1973 [50] 5 patients Debridement (3 cases), pin removal
(1 case), skin graft (1 case)
Oral therapy group: Oral group: Oral therapy:
lincomycin and clindamycin
alternately also gentamicin
maximum of 32 days pathogen cleared in 1 case but
both cases showed good response
Parenteral group: clindamycin Parenteral group: maximum
of 11 days
Parenteral group: pathogen
clearance and good response
in all cases
McCloskey 1977 [51] 3 patients Cefoxitin 12 days All were cured
Fass 1978 [52] 2 cases of femur osteomyelitis Wound aspiration
(1 case, not-speciﬁed)
Cefazolin and cephalexin Case 1: 46 days iv followed
by 22 days oral
Cured (21 and 34 months
follow-up)
Case 2: 14 days iv
Schurman and Dillingham 1979 [53] 6 patients Surgery (not clearly described) Cefoxitin Average 15 days (range 11–24) 4 patients were cured,
1 improved, 1 failed
Green and Ripley 1984 [54] 14 patients with chronic
osteomyelitis (12 tibia,
1 ulna, 1 radius)
Debridement and curettage in
all patients
Penicillin or cephalosporin
parenterally then orally
Parenteral for 12.2 days
(3–28 days) and oral for
76 days (0–150 days)
12 cases healed with a
follow-up of 2–6 months
Pottage et al. 1984 [55] 4 patients had chronic
osteomyelitis of tibia
3 cases treated with debridement,
1 with muscle ﬂap, and 1 with
omentum ﬂap and skin graft
Cefsulodin 4 g/day with
ampicillin (for Enterococcus)
or 8 g/day (2 cases)
42 days (2 cases), 26 days
(1 case) and 17 days (1 case)
Relapse twice in the same
patient after 3–4 months
Follow-up: 3/11/12/32 months
Romero-Vivas et al. 1985 [56] 2 patients with chronic
osteomyelitis
Debridement of wound infections
and curettage
Aztreonam and penicillin for
one patient; cloxacillin for
the 2nd patient
7–44 days (the exact period
is not known as the patients
were part of a group with
other infections)
Follow-up for 3 months,
6 patients improved
Reinhardt et al. 1986 [57] 14 osteomyelitis cases Ampicillin and sulbactam
with/without gentamicin, or
clindamycin with gentamicin
or clindamycin alone
27 days (9–42 days) All had satisfactory clinical
responses
Lo¨fﬂer et al. 1986 [58] (1) 2 chronic osteomyelitis (1) 1 g of sulbactam and 2g of
ampicillin q3d
Both groups treated for 2 weeks (1) Both cases cured
(2) 1 chronic osteomyelitis (2) Cefotaxime 2g q3d (2) Patient relapsed
Knopp et al. 1987 [59] 47 cases of chronic osteomyelitis 15 latissimus dorsi muscle
myocutaneous and 32 local ﬂaps
Antibiotic type not speciﬁed 3–5 days Mean follow-up of 2.5 years:
40 successes (85%)
Meibner et al. 1989 [60] 60 patients with chronic
post-traumatic
Fosfomycin 5–28 days (mean 13.9 days) Mean follow-up of 37 months
(7–53 months); outcome was
very good in 54.7%, good in
3.8% and satisfactory in 15.1%
osteomyelitis with 43 tibia
and 13 femur cases
Gentry and Rodriguez 1990 [61] 67 patients with chronic bone
osteomyelitis (tibia and femur)
Surgical debridement and removal
of metallic material
Ciproﬂoxacin vs. broad
spectrum cephalosporin
Average 56 days (28–96 days)
for ciproﬂoxacin; 47 days
(8–77 days) for iv regimen
Follow-up: 12 months; success
rate 77% with ciproﬂoxacin vs.
79% with the iv regimen
Shcherbin et al. 1990 [62] 33 patients with chronic gunshot
osteomyelitis
Radical surgical intervention,
debridement, irrigation and
drainage
Lincomycin and gentamicin 7–22 days Follow-up for 4 years showed
3 relapses out of 26 operated
patients
Greenberg 1990 [63] 26 patients with chronic
osteomyelitis
Debridement or vascular repair
or both when needed
Teicoplanin Range 1–13 days All improved but further
assessment was not done
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pathology of the disease.
In chronic osteomyelitis, the sustained suppurative infection of
the bone results in tissue necrosis and vascular collapse. The
ischemia exacerbates the bone necrosis and parts of the infected
bone lacking blood supply become separated into certain foci
called sequestra.2 Antibiotics and the inﬂammatory cells of the
host are unable to reach these avascular envelopes causing chronic
disease,2 unless there is surgical manipulation through debride-
ment, drainage, and soft tissue coverage. Additionally, the surgical
procedure helps in diminishing the microbial load, eradicating the
unviable tissues, and revitalizing the dead space with healthy soft-
tissue and neovascularization. The enhanced blood perfusion to
the bone improves the bioavailability of the antimicrobial drug and
certain physiological contributors, consequently ﬁghting the
infection and promoting tissue healing.2 Hence the importance
of the revascularization timeline in estimating the duration of
antibiotic use.
Muscle ﬂap versus control group studies in chronic osteomye-
litis showed better blood ﬂow, increased antibiotic release, and
decreased bacterial count in the muscle ﬂap group.12 Recent
advances in surgical technology andmicrosurgery have reﬁned the
ﬂap harvest14 and developed its hemodynamics,12 allowing the re-
establishment of a blood supply earlier than what was previously
expected. Since revascularization or blood supply is a major factor
in determining the antibiotic treatment duration, it is generally
proposed that the proper surgical intervention can help not only
reduce the failure rate but also shorten the duration of antibiotic
therapy. Recently, Rubino et al. reported the case of a woman with
chronic osteomyelitis in the lower extremities that was treated
with intravenous antibiotics for only 2 weeks following radical
excision and obliteration of the dead space with a propeller ﬂap.
She recovered with no relapse within a year.12 Further studies
indicating short-term antibiotic treatment of osteomyelitis are
summarized in Table 2.
Therefore, shorter duration of antimicrobial treatment with
emphasis on thorough debridement and well-vascularized ﬂap
coverage might be a possible alternative guideline for treating
chronic osteomyelitis in the lower extremities. Of course further
studies are necessary to build a scientiﬁc basis for themanagement
of the precise duration of antibiotics in the light of enhanced
surgical intervention. These studies should focus on blood ﬂow and
revascularization of bone following ﬂap introduction, in order to
instigate clinical studies regarding treatment of chronic osteomy-
elitis with shorter antibiotic regimens following enhanced surgical
intervention.
9. Conclusions
Chronic osteomyelitis is a relatively common infection and is
often a lifelong disease. Despite all of the advances in antibiotic
and operative treatment, osteomyelitis remains difﬁcult to treat.
This is because bacteria can elude host defense mechanisms by
hiding intracellularly and by developing a protective slimy coat.
By acquiring a very slow metabolic rate, bacteria become less
sensitive to antibiotics. For all the above reasons, operative
treatment is considered whenever possible. Osteomyelitis has
traditionally been treated with 4–6 weeks of parenteral
antibiotics after deﬁnitive debridement surgery. However, this
time frame has no documented superiority over other time
intervals, and there is no evidence that prolonged parenteral
antibiotics will penetrate the necrotic bone. A small number of
comparative trials on the treatment of chronic osteomyelitis
have been published. However, most of the studies have involved
relatively few patients and have not been randomized. It should
be added here that the type of surgical procedures practiced in
R. Haidar et al. / International Journal of Infectious Diseases 14 (2010) e752–e758 e757the past in treating chronic osteomyelitis and the lack of effective
muscle ﬂap application might have contributed to the prolonged
antibiotic treatment. And although the surgical approach in
treating chronic osteomyelitis has advanced markedly, the same
duration of antibiotic treatment is still adopted. Properly
designed studies are needed to ascertain the optimal duration
of antibiotic treatment for patients with chronic osteomyelitis.
Also more studies are needed to clarify the role of angiogenesis in
the treatment of chronic osteomyelitis.
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